Results 211 to 220 of about 51,073 (294)

Polypharmacy driven synergistic toxicities in elderly breast cancer chemotherapy drug management and adverse drug reactions: a mini review. [PDF]

Front Pharmacol
Wang X, Yang J, Zhang J, Yang H.
europepmc   +1 more source

Regional variation in antipsychotic polypharmacy for schizophrenia [PDF]

, 2011
Amanda Wheeler
openalex   +1 more source

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Type 2 diabetes mellitus (T2DM) is a progressive disease involving multiple pathophysiologic defects, and combination therapy is often required to achieve and sustain glycaemic control. Triple oral therapy with metformin, dipeptidyl peptidase‐4 inhibitors (DPP‐4i), and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) has demonstrated high ...
Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao, Steering Committee, Development Group, The Diabetes Committee of the Chinese Research Hospital Association   +15 more
wiley   +1 more source

Target trial emulation of statin discontinuation in multimorbid older adults with polypharmacy

European Journal of Clinical Investigation, EarlyView.
In this target trial emulation in multimorbid older adults with polypharmacy, statin discontinuation was associated with a higher rate of non‐cardiovascular mortality, suggesting residual confounding by indication. Unlike some previous retrospective cohort studies, there was no clear evidence of increased cardiovascular events arising from statin ...
Valerie Aponte Ribero, Oliver Baretella, Cinzia Del Giovane, Moa Haller, Martin Feller, Benoît Boland, Antoine Christiaens, Wilma Knol, Denis O'Mahony, Viktoria Gastens, Baris Gencer, Stéphanie Baggio, Nicolas Rodondi   +12 more
wiley   +1 more source

Polypharmacy and associated factors among patients with type two diabetes mellitus with comorbidity: a multicenter cross-sectional study in Northwest Ethiopia. [PDF]

BMC Endocr Disord
Tamene FB, Zeleke TK, Desalew AF, Tarekegn GY, Sendekie AK, Tafere SM, Kiflu M, Moges TA, Dagnew FN, Wondm SA.   +9 more
europepmc   +1 more source

From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real‐World Evidence

European Journal of Haematology, EarlyView.
ABSTRACT B‐cell maturation antigen (BCMA)‐directed chimeric antigen receptor (CAR) T‐cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) are the only BCMA‐targeted CAR T‐cell therapies approved by the FDA.
Hector Garcia Pleitez, Sakditad Saowapa, Andrea Ortiz Maldonado, Chanakarn Kanitthamniyom, Diego Olavarria Bernal, Lukman Tijani   +5 more
wiley   +1 more source

Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions. [PDF]

J Eval Clin Pract
Ngcobo NN.
europepmc   +1 more source

Polypharmacy in psychiatric outpatient practice in northern Nigeria

, 2008
Ademola Adeponle, Abiodun Obembe, Shola Adeyemi, G T Suleiman   +3 more
openalex   +2 more sources

Role of Frailty in Assessing Eligibility for CAR T‐Cell Therapy in Haematology

European Journal of Haematology, EarlyView.
ABSTRACT Background and Objectives Frailty is a key consideration in determining whether a patient is robust enough for CAR T‐cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T‐cell therapy ...
Jennifer Clesham, Joan McGrory, Aoife Bannon, Deirbhle Cox, Maura Dowling   +4 more
wiley   +1 more source